JP2019527231A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019527231A5 JP2019527231A5 JP2019504928A JP2019504928A JP2019527231A5 JP 2019527231 A5 JP2019527231 A5 JP 2019527231A5 JP 2019504928 A JP2019504928 A JP 2019504928A JP 2019504928 A JP2019504928 A JP 2019504928A JP 2019527231 A5 JP2019527231 A5 JP 2019527231A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- combination
- subject
- sarcoma
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662369639P | 2016-08-01 | 2016-08-01 | |
| US62/369,639 | 2016-08-01 | ||
| PCT/US2017/044513 WO2018026663A1 (en) | 2016-08-01 | 2017-07-28 | Combinations for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019527231A JP2019527231A (ja) | 2019-09-26 |
| JP2019527231A5 true JP2019527231A5 (https=) | 2020-09-10 |
Family
ID=61073280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019504928A Pending JP2019527231A (ja) | 2016-08-01 | 2017-07-28 | がんを治療するための組み合わせ |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20190185567A1 (https=) |
| EP (1) | EP3490561A4 (https=) |
| JP (1) | JP2019527231A (https=) |
| CN (1) | CN109689056A (https=) |
| WO (1) | WO2018026663A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11970486B2 (en) | 2016-10-24 | 2024-04-30 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| EA201991650A1 (ru) | 2017-01-06 | 2020-01-20 | Юманити Терапьютикс, Инк. | Способы лечения неврологических расстройств |
| CA3083000A1 (en) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| US11247990B1 (en) | 2017-12-07 | 2022-02-15 | Array Biopharma Inc | Bicyclic fused pyridine compounds as inhibitors of TAM kinases |
| BR112020019191A2 (pt) | 2018-03-23 | 2021-01-05 | Yumanity Therapeutics, Inc. | Compostos e seus usos |
| UY38349A (es) | 2018-08-30 | 2020-03-31 | Array Biopharma Inc | Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met |
| MX2021008903A (es) | 2019-01-24 | 2021-11-04 | Yumanity Therapeutics Inc | Compuestos y usos de los mismos. |
| WO2020198026A1 (en) * | 2019-03-22 | 2020-10-01 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| EA202192047A1 (ru) | 2019-11-13 | 2021-12-08 | Юманити Терапьютикс, Инк. | Соединения и их применение |
| AU2019474803B2 (en) * | 2019-11-19 | 2024-11-07 | Provectus Pharmatech, Inc. | Composition and method for treating hematologic cancers |
| US11419844B2 (en) | 2019-11-19 | 2022-08-23 | Provectus Pharmatech, Inc. | Halogenated xanthene composition and method for treating hematologic cancers |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL148079A0 (en) * | 1999-08-24 | 2002-09-12 | Medarex Inc | Human ctla-4 antibodies and compositions containing the same |
| AU2015203322B2 (en) * | 2009-07-20 | 2016-09-29 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
| SMT201700293T1 (it) * | 2009-07-20 | 2017-07-18 | Bristol Myers Squibb Co | Combinazione di un anticorpo anti-ctla-4 con etoposide per il trattamento sinergico di malattie proliferative |
| WO2012027536A1 (en) * | 2010-08-26 | 2012-03-01 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with braf inhibitors for the synergistic treatment of proliferative diseases |
| EP2714081A4 (en) * | 2011-05-27 | 2015-09-09 | Cytocure Llc | METHODS, COMPOSITIONS AND KIT FOR CREAM TREATMENT |
| EP2780338B1 (en) * | 2011-11-14 | 2016-11-09 | Ignyta, Inc. | Uracil derivatives as axl and c-met kinase inhibitors |
| HK1226058A1 (zh) * | 2013-08-02 | 2017-09-22 | 亚尼塔公司 | 单独地或与其它试剂联合地使用axl/cmet抑制剂治疗多种癌症的方法 |
| WO2015116868A2 (en) * | 2014-01-29 | 2015-08-06 | Caris Mpi, Inc. | Molecular profiling of immune modulators |
| US10231965B2 (en) * | 2014-02-20 | 2019-03-19 | Ignyta, Inc. | Molecules for administration to ROS1 mutant cancer cells |
-
2017
- 2017-07-28 CN CN201780056390.6A patent/CN109689056A/zh active Pending
- 2017-07-28 EP EP17837447.6A patent/EP3490561A4/en not_active Withdrawn
- 2017-07-28 WO PCT/US2017/044513 patent/WO2018026663A1/en not_active Ceased
- 2017-07-28 JP JP2019504928A patent/JP2019527231A/ja active Pending
- 2017-07-28 US US16/322,926 patent/US20190185567A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019527231A5 (https=) | ||
| JP2019524851A5 (https=) | ||
| CN105849110B (zh) | 使用溴结构域和额外终端(bet)蛋白抑制剂的用于癌症的组合疗法 | |
| ES2751300T3 (es) | Formulación sublingual de riluzol | |
| RU2012151571A (ru) | Лекарственные препараты для лечения рака | |
| CN103547315A (zh) | 用于治疗腺样囊性癌的4-氨基-5-氟-3-[6-(4-甲基哌嗪-1-基)-1h-苯并咪唑-2-基]-1h-喹啉-2-酮 | |
| TWI762784B (zh) | Cdk4/6抑制劑與egfr抑制劑聯合在製備治療腫瘤疾病的藥物中的用途 | |
| RU2005128791A (ru) | Лекарственные формы, содержащие ag013736 | |
| JPWO2019209896A5 (https=) | ||
| CN115006397A (zh) | 一种预防或治疗肿瘤疾病的药物用途 | |
| JPWO2020229626A5 (https=) | ||
| US20090005406A1 (en) | Cancer Treatment Method | |
| JPWO2019154986A5 (https=) | ||
| JP2004510761A5 (https=) | ||
| TW202042810A (zh) | 一種含cdk4/6抑制劑的組合物與阿那曲唑聯合在製備治療腫瘤疾病的藥物中的用途 | |
| CN108472323B (zh) | 包含藻蛋白多糖提取物的组合物及其用途 | |
| KR102744499B1 (ko) | 비인두암을 치료하기 위한 퀴놀린 유도체 | |
| Lucendo et al. | Esophageal granular cell tumor and eosinophilic esophagitis: two interesting entities identified in the same patient | |
| WO2022123427A1 (en) | Methods of identifying a tumor that is sensitive to treatment with talazoparib and methods of treatment thereof | |
| PT1757283E (pt) | Potenciador do efeito antitumoral, agente antitumoral e método para a terapia do cancro | |
| Chao-Cheng et al. | Lipoblastomatosis combined with intestinal neuronal dysplasia | |
| CN118019537A (zh) | Shp2抑制剂联合egfr-tki治疗和预防肿瘤疾病的医药用途 | |
| RU2718048C2 (ru) | Противоопухолевое терапевтическое средство | |
| Bendre | A Comparative Study of Ondansetron With Dexamethasone & Granisetron With Dexamethasone For Prevention of Postoperative Nausea & Vomiting Following Abdominal Surgeries Under General Operations. | |
| TW202547488A (zh) | 於癌症的治療中之化合物Ｉａ和拓樸異構酶Ｉ抑制劑的組合 |